Delivery Order SPE2DB22D1103-SPE2DB25FTNT7
- Not listed
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in treating inflammatory conditions. The contract was awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on June 2, 2025, with an ultimate completion date of June 3, 2025. This is a firm fixed price delivery order with no set-aside designation, executed competitively under AmerisourceBergen's broader contract vehicle with DLA. The product will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order contract valued at $2,265.90 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. The contract was awarded on June 18, 2025, with an ultimate completion date of June 20, 2025, and operates under a firm fixed price structure with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $10,610.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $19,051.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The award, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a $26,259.86 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 25, 2025, with an ultimate completion date of August 26, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,021.20 on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This is a firm fixed-price, non-set-aside competitive award with a performance location in Conshohocken, Pennsylvania, and an ultimate completion date of August 14, 2025. The delivery order represents a single transaction under AmerisourceBergen's larger federal contract vehicle with the Defense Logistics Agency. This delivery...
- The Defense Logistics Agency awarded a $3,776.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of July 23, 2025. This competitive award, issued on July 22, 2025, carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The performance...
- The Defense Logistics Agency awarded a $2,795.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, with a completion date of June 2, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationships with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTNT7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,056.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies. This competitively awarded, firm fixed-price contract was issued on June 2, 2025, with an ultimate completion date of June 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which holds a potential value of $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military and federal healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. HUMIRA is a widely used biologic medication for treating inflammatory conditions, and this specific delivery order fulfills immediate pharmaceutical supply needs within DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 6/2/25 |